MYGN
Myriad Genetics IncCompany with tickers: MYGN
CIK
899923
CUSIP
62855J104
Shares Outstanding
94,448,210
Website
https://www.myriad.com
Investor Relations
https://investor.myriad.com/
13F Activity (30d)
6 filings
2 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $200,400,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Cost of Revenue | — | ||||
| Gross Profit | $137,600,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Operating Expenses | $168,300,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Research & Development | $27,100,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Operating Income | $-30,700,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Net Income | $-34,100,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| EPS (Basic) | $-0.36 | USD/shares | 2026-03-31 | 10-Q | 2026-05-06 |
| EPS (Diluted) | $-0.36 | USD/shares | 2026-03-31 | 10-Q | 2026-05-06 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Geography (USD)
| Component | 2019-06-30 | 2020-06-30 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|---|---|
| United States | $805,400,000 | $596,200,000 | $603,700,000 | $591,500,000 | $671,700,000 | $769,500,000 | $768,000,000 |
| Non Us | $45,700,000 | $42,400,000 | $86,900,000 | $86,900,000 | $81,500,000 | $68,100,000 | $56,500,000 |
By Product & Service (USD)
| Component | 2019-06-30 | 2020-06-30 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|---|---|---|
| Hereditary Cancer | — | — | — | — | $305,500,000 | $327,800,000 | $364,500,000 | $372,400,000 |
| Prenatal | — | — | — | — | $116,400,000 | $151,300,000 | $177,100,000 | $186,300,000 |
| Mental Health | — | — | — | — | — | $138,500,000 | $170,200,000 | $144,100,000 |
| Tumor Profiling | — | $48,300,000 | — | $120,900,000 | $128,600,000 | $135,600,000 | $125,800,000 | $121,700,000 |
| Autoimmune | — | $39,100,000 | — | $28,200,000 | $300,000 | — | — | — |
| Hereditary Cancer Testing | — | $347,400,000 | — | $316,300,000 | — | — | — | — |
| Molecular Diagnostic Autoimmune | $48,300,000 | $39,100,000 | — | $28,200,000 | — | — | — | — |
| Molecular Diagnostic Hereditary Cancer Testing | $479,700,000 | $347,400,000 | — | $316,300,000 | — | — | — | — |
| Molecular Diagnostic Other Testing | $900,000 | $1,300,000 | — | $500,000 | — | — | — | — |
| Molecular Diagnostic Pharmacogenomics | $112,600,000 | $74,100,000 | — | $93,700,000 | — | — | — | — |
| Molecular Diagnostic Prenatal Testing | $104,900,000 | $76,700,000 | — | $106,800,000 | — | — | — | — |
| Molecular Diagnostic Testing | $789,400,000 | $586,900,000 | $513,500,000 | $666,400,000 | — | — | — | — |
| Molecular Diagnostic Tumor Profiling | $43,000,000 | $48,300,000 | — | $120,900,000 | — | — | — | — |
| Other Testing | — | $1,300,000 | — | $500,000 | — | — | — | — |
| Pharmaceutical And Clinical Services | $61,700,000 | $51,700,000 | $43,600,000 | $24,200,000 | — | — | — | — |
| Pharmacogenomics | — | $74,100,000 | — | $93,700,000 | $127,600,000 | — | — | — |
| Prenatal Testing | — | $76,700,000 | — | $106,800,000 | — | — | — | — |
| Testing Revenue | — | $586,900,000 | — | $666,400,000 | — | — | — | — |
| Product And Service Other | — | $51,700,000 | — | $24,200,000 | — | — | — | — |